Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMW23Y9)

• Drug Name: GTP-14564 Drug Info
• Synonyms: GTP-14564; GTP 14564; 34823-86-4; 3-Phenyl-1H-benzofuro[3,2-c]pyrazole; 1-Phenyl-3-H-8-oxa-2,3-diaza-cyclopenta[a]inden; CHEMBL406375; 3-phenyl-1H-[1]benzofuro[3,2-c]pyrazole; 3-Phenyl-1H-benzofuro(3,2-c)pyrazole; AC1MPHAI; SCHEMBL2550165; GTPL5982; CHEBI:92300; DTXSID10188363; MolPort-002-816-012; HMS3268J15; HMS3229E17; ZINC5387628; HSCI1_000176; BDBM50375646; AKOS024456938; MCULE-3563628731; CCG-206757; NCGC00159539-01; AI-204/33265070; J-019773; BRD-K16664969-001-02-5; BRD-K16664969-001-01-7

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3385203
  ChEBI ID: CHEBI:92300
  CAS Number: CAS 34823-86-4
  TTD Drug ID: DMW23Y9

Molecule-Related Drug Atlas

Drug(s) Targeting CSF1R messenger RNA (CSF1R mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JNJ-28312141	DMCMH7O	Discovery agent	N.A.	Investigative	[2]
Ki-20227	DM9M3VC	Discovery agent	N.A.	Investigative	[2]
GW-2580	DMTW9GM	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Tyrosine-protein kinase Kit (KIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[5]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[6]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[7]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[7]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[8]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[9]
Ripretinib	DM958QB	Gastrointestinal stromal tumour	2B5B	Approved	[10]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[12]

Drug(s) Targeting Platelet-derived growth factor receptor beta (PDGFRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[5]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[13]
Becaplermin	DM1R5X4	Diabetic complication	5A2Y	Approved	[14]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[15]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[12]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[16]
SNN-0031	DM2X3BR	Brain injury	NA07.Z	Phase 1/2	[17]
TAK-593	DMNFZOT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
Pyridine derivative 18	DMBZMYT	N. A.	N. A.	Patented	[19]

Drug(s) Targeting Fms-like tyrosine kinase 3 (FLT-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[20]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[7]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[21]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[4]
Gilteritinib	DMTI0ZO	Acute myeloid leukaemia	2A60	Approved	[22]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[9]
Pacritinib	DM1T6ZN	Myelofibrosis	2A20.2	Approved	[20]
Quizartinib	DM8Y4JS	Acute myeloid leukaemia	2A60	Approved	[23]
Lestaurtinib	DMQ2AIJ	Acute myeloid leukaemia	2A60	Approved (orphan drug)	[24]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CSF1R messenger RNA (CSF1R mRNA)	TTVW6QL	CSF1R_HUMAN	Inhibitor	[1]
Fms-like tyrosine kinase 3 (FLT-3)	TTGJCWZ	FLT3_HUMAN	Inhibitor	[1]
Platelet-derived growth factor receptor beta (PDGFRB)	TTI7421	PGFRB_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase Kit (KIT)	TTX41N9	KIT_HUMAN	Inhibitor	[1]

References

• [1] Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosin... J Biol Chem. 2003 Aug 29;278(35):32892-8.
• [2] Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
• [3] Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83.
• [4] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [5] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [6] New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [11] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [12] National Cancer Institute Drug Dictionary (drug id 452042).
• [13] Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [16] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [17] Company report (Neuronova)
• [18] Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
• [19] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
• [21] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [22] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [23] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [24] Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.